Artificial Intelligence (AI) In Respiratory Diseases Market Report 2026

Artificial Intelligence (AI) In Respiratory Diseases Market Overview

• Artificial Intelligence (AI) In Respiratory Diseases market size has reached to $7.98 billion in 2025 • Expected to grow to $10.19 billion in 2030 at a compound annual growth rate (CAGR) of 5% • Growth Driver: AI Revolutionizing Respiratory Health Addressing The Impact Of Growing Environmental Pollution • Market Trend: TidalSense Launches N-Tidal Device For AI-Driven Respiratory Disease Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Intelligence (AI) In Respiratory Diseases Market?

Artificial intelligence (AI) in respiratory diseases refers to the use of AI and machine learning techniques to aid clinicians in the diagnosis, management, and treatment of various respiratory conditions. It has numerous potential applications in pulmonary medicine, including image analysis, predictive modeling, and disease management. The main imaging types of artificial intelligence (AI) in respiratory diseases are magnetic resonance imaging (MRI), computed tomography (CT) scan, and electronic patient-reported outcomes (ePRO). AI in chronic obstructive pulmonary disease refers to the application of artificial intelligence (AI) technologies in the diagnosis, management, and treatment of COPD. It is used for the treatment of various indications such as chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary infection, by several end-users, including hospital, diagnostic centers, ambulatory surgical centers, and others.

What Is The Artificial Intelligence (AI) In Respiratory Diseases Market Growth Forecast?

The artificial intelligence (ai) in respiratory diseases market size is expected to see strong growth in the next few years. It will grow to $10.19 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing demand for personalized respiratory care, rising integration of ai with clinical decision support systems, expansion of remote monitoring for chronic respiratory patients, growing focus on preventive pulmonology, advancements in medical imaging ai. Major trends in the forecast period include increasing use of AI-based imaging analysis, rising adoption of predictive disease progression models, growing integration of ai in pulmonary diagnostics, expansion of remote respiratory monitoring solutions, enhanced focus on early disease detection.

Global Artificial Intelligence (AI) In Respiratory Diseases Market Segmentation

1) By Imaging Type: Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Electronic Patient-Reported Outcomes (ePRO) 2) By Indication: Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Pulmonary Infection 3) By End Use: Hospital, Diagnostic Centers, Ambulatory Surgical Centers, Other End-Users Subsegments: 1) By Magnetic Resonance Imaging (MRI): Lung Imaging, Thoracic Imaging, Cardiopulmonary Imaging 2) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Low-Dose CT, Thoracic CT 3) By Electronic Patient-Reported Outcomes (ePRO): Symptom Tracking, Medication Adherence Monitoring, Quality Of Life Assessments

What Is The Driver Of The Artificial Intelligence (AI) In Respiratory Diseases Market?

respiratory disease market going forward. Environmental pollution refers to the addition of any substance or form of energy to the environment at a rate faster than it can be dispersed or stored in a harmless form. AI in respiratory diseases has the potential to significantly reduce the impact of environmental pollution on respiratory health by offering real-time monitoring, personalized risk assessments, informed decision-making, and innovative solutions for both individuals and communities. For instance, in November 2024, according to the Global Carbon Budget, a Japan-based annual scientific assessment, fossil carbon dioxide emissions climbed to 37.4 billion tonnes, an increase of 0.8% over the previous year. Therefore, growing environmental pollution is driving the growth of artificial intelligence (AI) in the respiratory disease market.

Key Players In The Global Artificial Intelligence (AI) In Respiratory Diseases Market

Major companies operating in the artificial intelligence (AI) in respiratory diseases market are Siemens Healthineers, Philips Healthcare, GE Healthcare, Verily Life Sciences LLC, DeepMind Health, Merative L.P., Aidoc Medical, Butterfly Network, Infervision, Imagen Technologies, Caption Health, Swaasa AI, VIDA Diagnostics Inc., Enlitic, Thirona B.V., ArtiQ, Icometrix, Aidence, Arterys, PneumoWave Ltd

Global Artificial Intelligence (AI) In Respiratory Diseases Market Trends and Insights

Major companies operating in artificial intelligence (AI) in the respiratory diseases market are developing innovative products such as N-Tidal devices to monitor patients' tidal breathing. The n-Tidal device measures the volume of air exchanged during normal breathing and provides valuable information about lung function. For instance, in August 2023, TidalSense, a UK-based respiratory technology company, launched N-Tidal, a regulated AI technology for chronic obstructive pulmonary disease (COPD) diagnosis and management. The technology combines N-Tidal's CO2 sensor data with an artificial intelligence platform to measure changes in lung function, aiming to improve the diagnosis and management of this respiratory condition. Clinical studies have demonstrated the technology's high accuracy, and it is expected to reform the diagnostic process for respiratory diseases. The launch is a significant development in the use of AI for respiratory disease assessment, offering a more comfortable and efficient alternative to existing diagnostic tests.

What Are Latest Mergers And Acquisitions In The Artificial Intelligence (AI) In Respiratory Diseases Market?

In July 2023, ResMed Inc., a US-based medical equipment company that provides cloud-connectable medical devices, acquired Somnoware for an undisclosed amount. This acquisition strengthens ResMed's sleep and respiratory care portfolio and complements its existing digital respiratory healthcare tools. The acquisition is expected to enhance the management of patient data, ordering of treatment equipment, scheduling appointments, and tracking compliance, ultimately improving patient experience and health outcomes. Somnoware is a US-based, cloud-based platform for enhanced respiratory care management and hospital-at-home care.

Regional Outlook

North America was the largest region in the artificial Intelligence (AI) in respiratory diseases market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Artificial Intelligence (AI) In Respiratory Diseases Market?

The artificial Intelligence (AI) in respiratory diseases market includes revenues earned by entities by providing services such as AI-assisted imaging analysis, digital pathology platforms, and AI-powered rehabilitation programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The AI in respiratory diseases market also includes sales IoT devices, wearables, and smart inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Artificial Intelligence (AI) In Respiratory Diseases Market Report 2026?

The artificial intelligence (ai) in respiratory diseases market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (ai) in respiratory diseases industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.